A Bagust

Summary

Affiliation: University of York
Country: UK

Publications

  1. pmc Dynamics of bed use in accommodating emergency admissions: stochastic simulation model
    A Bagust
    York Health Economics Consortium, University of York, Heslington, York YO10 5DD
    BMJ 319:155-8. 1999
  2. ncbi An alternative to body mass index for standardizing body weight for stature
    A Bagust
    Prescribing Research Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    QJM 93:589-96. 2000
  3. ncbi Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials
    A Bagust
    York Health Economics Consortium, University of York, Heslington, YO10 5EL, York, UK
    Eur J Cancer 37:1081-8. 2001
  4. ncbi Deteriorating beta-cell function in type 2 diabetes: a long-term model
    A Bagust
    York Health Economics Consortium, University of York, Heslington, UK
    QJM 96:281-8. 2003
  5. ncbi An economic model of the long-term health care burden of Type II diabetes
    A Bagust
    York Health Economics Consortium, University of York, Heslington, York, YO10 5DD, UK
    Diabetologia 44:2140-55. 2001
  6. ncbi The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060
    A Bagust
    York Health Economics Consortium, University of York, Heslington, York, UK
    Diabet Med 19:1-5. 2002
  7. ncbi Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:47-53. 2010
  8. doi Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, The Quadrangle, Brownlow Hill, Liverpool, UK
    Health Technol Assess 14:33-9. 2010
  9. ncbi Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 13:49-54. 2009
  10. doi Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-93, iii-iv. 2011

Collaborators

Detail Information

Publications36

  1. pmc Dynamics of bed use in accommodating emergency admissions: stochastic simulation model
    A Bagust
    York Health Economics Consortium, University of York, Heslington, York YO10 5DD
    BMJ 319:155-8. 1999
    ....
  2. ncbi An alternative to body mass index for standardizing body weight for stature
    A Bagust
    Prescribing Research Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    QJM 93:589-96. 2000
    ..3% for males, 21.1% for females). Physical dysfunction and self-reported poor health showed strong trends with excess body weight. These findings need confirmation from larger population samples...
  3. ncbi Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials
    A Bagust
    York Health Economics Consortium, University of York, Heslington, YO10 5EL, York, UK
    Eur J Cancer 37:1081-8. 2001
    ..This approach yields relative weightings and rankings for the main issues affecting QoL ratings in lung cancer patients, most importantly fatigue, breathlessness, poor concentration and disruption to family and social life...
  4. ncbi Deteriorating beta-cell function in type 2 diabetes: a long-term model
    A Bagust
    York Health Economics Consortium, University of York, Heslington, UK
    QJM 96:281-8. 2003
    ..Although the former is already established at diagnosis and changes little thereafter, beta-cell function continues to decline, leading to secondary failure of anti-hyperglycaemic therapies...
  5. ncbi An economic model of the long-term health care burden of Type II diabetes
    A Bagust
    York Health Economics Consortium, University of York, Heslington, York, YO10 5DD, UK
    Diabetologia 44:2140-55. 2001
    ....
  6. ncbi The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060
    A Bagust
    York Health Economics Consortium, University of York, Heslington, York, UK
    Diabet Med 19:1-5. 2002
    ..To predict the incidence and prevalence of Type 2 diabetes in the UK, the trends in the levels of diabetes-related complications, and the associated health care costs for the period 2000-60...
  7. ncbi Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:47-53. 2010
    ....
  8. doi Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, The Quadrangle, Brownlow Hill, Liverpool, UK
    Health Technol Assess 14:33-9. 2010
    ....
  9. ncbi Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 13:49-54. 2009
    ....
  10. doi Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-93, iii-iv. 2011
    ..Hormone receptor status and human epidermal growth factor 2 (HER2) status are two predictive factors that are taken into consideration when estimating the prognosis of patients with breast cancer...
  11. doi Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    T Brown
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:71-9. 2010
    ....
  12. doi Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
    A Boland
    Liverpool Reviews and Implementation Group, Sherrington Buildings, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:41-8. 2009
    ..Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted...
  13. doi Rituximab for the treatment of rheumatoid arthritis
    A Bagust
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:23-9. 2009
    ....
  14. doi Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
    T Brown
    Liverpool Reviews and Implementation Group LRiG, Institute of Psychology, Health and Society, Department of Health Services Research, University of Liverpool, Liverpool, UK
    Health Technol Assess 17:1-278. 2013
    ..This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance...
  15. doi Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
    J Greenhalgh
    Liverpool Reviews and Implementation Group LRiG, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-178. 2011
    ..The primary objective in the treatment of all patients with a history of occlusive vascular events and peripheral arterial disease is to prevent the occurrence of new occlusive vascular events...
  16. doi Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy
    C Martin Saborido
    Liverpool Reviews and Implementation Group LRiG, Liverpool, UK
    Health Technol Assess 14:iii-iv, 1-75. 2010
    ..9 to 1.1), and reported prevalence rates show wide variations depending on age and country. Conventional treatment strategies for PAF focus on the suppression of paroxysms of AF and return to normal sinus rhythm...
  17. ncbi Erlotinib for the treatment of relapsed non-small cell lung cancer
    C McLeod
    Liverpool Reviews and Implementation Group LRiG, Room B05, Whelan Building, The Quadrangle, Brownlow Hill, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:41-7. 2009
    ..The guidance issued by NICE in February 2007 as a result of the STA states that erlotinib is not recommended for the treatment of locally advanced or metastatic NSCLC...
  18. ncbi Drug-eluting stents: a systematic review and economic evaluation
    R A Hill
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 11:iii, xi-221. 2007
    ..To assess the effectiveness and cost-effectiveness of the use of drug-eluting coronary artery stents in percutaneous coronary intervention (PCI) in patients with coronary artery disease...
  19. ncbi Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:31-8. 2010
    ..At the time of writing, the guidance/has not yet been published by NICE...
  20. ncbi Coronary artery stents: a rapid systematic review and economic evaluation
    R Hill
    Liverpool Reviews and Implementation Group, Liverpool, UK
    Health Technol Assess 8:iii-iv, 1-242. 2004
    ..To assess the effectiveness and cost-effectiveness of the use of coronary artery stents in patients with coronary heart disease (CHD)...
  21. ncbi The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation
    J C Hockenhull
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 12:iii-iv, xi-xii, 1-154. 2008
    ..To assess the clinical effectiveness and cost-effectiveness of central venous catheters (CVCs) treated with anti-infective agents in preventing catheter-related bloodstream infection (CRBSI)...
  22. ncbi Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation
    Y Dundar
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 11:1-90. 2007
    ..To assess the clinical effectiveness and cost-effectiveness of pemetrexed disodium in combination with cisplatin for the treatment of unresectable pleural mesothelioma in chemotherapy-naive patients...
  23. doi Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
    C McLeod
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 13:iii-iv, ix-xi, 1-121. 2009
    ....
  24. doi The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 14:1-157, iii. 2010
    ....
  25. ncbi Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
    Y Dundar
    Liverpool Reviews and Implementation Group LRiG, Liverpool, UK
    Health Technol Assess 13:23-8. 2009
    ....
  26. ncbi Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
    Y Dundar
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 8:iii-x, 1-125. 2004
    ..To assess the clinical and cost-effectiveness of zaleplon, zolpidem and zopiclone (Z-drugs) compared with benzodiazepines...
  27. ncbi The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature
    D A Hughes
    Prescribing Research Group, Department of Pharmacology and Therapeutics, University of Liverpool, UK
    Health Econ 10:601-15. 2001
    ..The importance of incorporating measures of compliance is highlighted, as failing to account for 'real world' compliance rates in pharmacoeconomic evaluations may lead to selection of sub-optimal treatment strategies...
  28. ncbi Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK
    A Shearer
    York Health Economics Consortium, University of York, Vanbrugh Way, Heslington, York, YO10 4NH, UK
    Diabet Med 21:460-7. 2004
    ..To determine the cost-effectiveness of a structured treatment and teaching programme (STTP) combining dietary freedom with insulin adjustment for Type 1 diabetes...
  29. ncbi A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses
    A Boland
    Prescribing Research Group, Department of Pharmacology and Therapeutics, University of Liverpool, UK
    Health Technol Assess 7:iii, ix-x, 1-99. 2003
    ..To examine the clinical and cost-effectiveness of image-guided Hickman line insertions versus blind Hickman line insertions undertaken by nurses in adult cancer patients...
  30. pmc Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study
    A Bagust
    University of Liverpool Management School, Liverpool, UK
    Heart 92:68-74. 2006
    ..To assess the cost effectiveness of drug eluting stents (DES) compared with conventional stents for treatment of symptomatic coronary artery disease in the UK...
  31. ncbi Accounting for noncompliance in pharmacoeconomic evaluations
    D A Hughes
    Prescribing Research Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Pharmacoeconomics 19:1185-97. 2001
    ....
  32. pmc Economic evaluation of an acute paediatric hospital at home clinical trial
    A Bagust
    Senior Research Fellow, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, UK
    Arch Dis Child 87:489-92. 2002
    ..To compare the privately borne and NHS costs of hospital at home (HAH) and conventional inpatient care for children with selected acute conditions...
  33. ncbi Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation
    A Boland
    Liverpool Reviews and Implementation Group, New Medical School, Liverpool, UK
    Health Technol Assess 7:1-136. 2003
  34. ncbi The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews
    C Black
    Department of Public Health, University of Aberdeen, UK
    Health Technol Assess 10:iii-iv, ix-x, 1-90. 2006
    ..The aim of this review is to examine the clinical and cost-effectiveness of screening for lung cancer using computed tomography (CT) to assist policy making and to clarify research needs...
  35. ncbi Evaluating the performance of the Framingham risk equations in a population with diabetes
    P McEwan
    School of Mathematics, Cardiff University, Cardiff, UK
    Diabet Med 21:318-23. 2004
    ..The purpose of this study was to evaluate the reliability of these equations in predicting CHD risk in people with diabetes and the reliability of using imputed mean HDL-cholesterol values...
  36. ncbi Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
    C McLeod
    Liverpool Reviews and Implementation Group, UK
    Health Technol Assess 11:1-158, iii-iv. 2007
    ..To assess the comparative clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis (AS)...